OncoBeta

The company’s lead product, Rhenium-SCT®, has demonstrated high efficacy for non-melanoma skin cancers. Published data report complete tumor regression in up to 98.5% of lesions treated, with most patients requiring only a single application and experiencing minimal pain or scarring. Scar-free healing typically occurs within weeks.

Clinical references include peer-reviewed studies showing strong safety and efficacy profiles for basal and squamous cell carcinomas.

The company continues to expand access to its therapy internationally, including recent launches in Italy.

An international registry for NMSC patients treated with Rhenium-SCT® was launched in late 2021 to further document outcomes.

No major adverse events or significant complications have been reported.

Regulatory status varies by country; the product appears commercially available at least in parts of Europe.

Pipeline breadth reflects a focus on this core technology/platform rather than multiple distinct drug candidates.